Top Exosome Companies Worldwide 2024
Exosome is another recent buzzword in the wellness and regenerative medicine space.
Exosomes are small vesicles ranging from 30-100nm in size that are found in nearly all eukaryotic fluids and facilitate a range of important cellular functions. They transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells.
In recent years, exosomes have gained attention as a strategy for accessing the therapeutic effects of cells without the risks and difficulties of administering the cells to patients.
With at least more than 23,000 scientific articles published about exosomes and more than 250 clinical trials underway, these small vesicles have intriguing potential to be used within a range of therapeutic applications.
The term “exosomes” has become an increasingly common Search Term on Google over the past 10 years.
Exosome Companies
Today, a rapidly growing number of companies are developing exosome-based products. The list below presents all known major exosome companies worldwide and the innovative technologies they are developing. While many of these companies are working alongside regulatory agencies, such as the U.S. FDA, all too many of them are not.Aegle Therapeutics
Aegle Therapeutics Corp. is a first in class, Phase 1/2a ready, biotechnology company isolating extracellular vesicles (“EVs”) from allogeneic bone marrow derived mesenchymal stem cells (BM-MSCs) to treat severe dermatological conditions, including burns and epidermolysis bullosa, a rare pediatric connective tissue disorder, and to prevent scarring. Aegle’s isolation process allows for the production of therapeutic-grade extracellular vesicles from bone marrow derived MSCs. In April of 2018, the U.S. Food and Drug Administration (FDA) cleared the company’s first Investigational New Drug (IND) application to begin clinical trials in burn patients.Aegle Therapeutics is a clinical-stage company developing exosome-based therapeutics for the treatment of a range of diseases, including acute and chronic inflammatory conditions, as well as tissue repair and regeneration. The company's platform utilizes natural exosomes derived from allogeneic mesenchymal stem cells (MSCs) to modulate the immune system and promote tissue repair. Aegle's lead product candidate, AGLE-102, is being evaluated in clinical trials for the treatment of multiple sclerosis (MS).
Country: United States City/State: Miami, FL Exosome Technology: Natural Exosomes Disease Targets: Inflammatory Conditions, Tissue Repair and Regeneration Description of Exosome Involvement: Aegle Therapeutics' exosome-based therapies utilize natural exosomes derived from allogeneic mesenchymal stem cells (MSCs) to modulate the immune system and promote tissue repair. Link to Exosome Programs: https://aegletherapeutics.com/pipeline/ Company Website: https://aegletherapeutics.com/
Aethlon Medical, Inc.
Aethlon Medical (NASDAQ: AEMD) is an American company focused on addressing unmet needs in global health and biodefense. It initiated its tumor-derived exosome research at a time when the medical community believed exosomes were cellular debris. Today, a therapeutic to address tumor-derived exosomes represents a significant unmet need in cancer care. Aethlon has demonstrated that the affinity mechanism of the Hemopurifier® can capture tumor-derived exosomes underlying several forms of cancer, including breast, ovarian and metastatic melanoma.The company's proprietary technology, the Aethlon Hemopurifier®, is an extracorporeal device designed to selectively capture and remove a range of viruses, including HIV and hepatitis C virus (HCV), as well as tumor-derived exosomes from circulation.
Country: United States City/State: San Diego, CA Exosome Technology: Exosome Capture Technology Disease Targets: Infectious Disease, Cancer Description of Exosome Involvement: Aethlon Medical's Aethlon Hemopurifier® technology is designed to capture and remove a range of viruses, including HIV and hepatitis C virus (HCV), as well as tumor-derived exosomes from circulation. Company Website: https://aethlonmedical.com/
Anjarium Biosciences AG
Anjarium Biosciences AG is a biotechnology company that is focused on the development of novel exosome-based therapies for the treatment of cancer.Hybridosomes® are nanoparticle shells of about 100 nm. Anjarium Bioscience’s Hybridosome® platform excels in conjunction with such optimized RNA modalities, providing an avenue to employ the potential of exosomes in RNA-based applications such as RNAi, mRNA replacement and gene editing. Coupled with the targeting technology and proprietary manufacturing methods, Anjarium’s Hybridosome® platform is a promising technology to overcome the delivery hurdles today’s most powerful RNA therapeutic candidates face.
The company's platform utilizes engineered exosomes to deliver therapeutic payloads, such as RNA and proteins, directly to cancer cells. Anjarium Biosciences AG is also developing diagnostic tests based on exosome biomarkers for the early detection of cancer.
Country: Switzerland City/State: Zurich Exosome Technology: Engineered Exosomes Disease Targets: Cancer Description of Exosome Involvement: Anjarium Biosciences AG's exosome-based therapies utilize engineered exosomes to deliver therapeutic payloads, such as RNA and proteins, directly to cancer cells. The company is also developing diagnostic tests based on exosome biomarkers for the early detection of cancer. Company Website: https://anjarium.com/
Aruna Bio
Aruna Bio is a biotechnology company focused on developing exosome-based therapies for the treatment of neurodegenerative diseases, including Parkinson's and Alzheimer's. The company's platform utilizes mesenchymal stem cell-derived exosomes to deliver therapeutic molecules, including RNA and proteins, directly to target cells in the central nervous system.Country: United States
City/State: La Jolla, CA
Exosome Technology: Mesenchymal Stem Cell-Derived Exosomes
Disease Targets: Neurodegenerative Diseases
Description of Exosome Involvement: Aruna Bio's exosome-based therapies utilize mesenchymal stem cell-derived exosomes to deliver therapeutic molecules, including RNA and proteins, directly to target cells in the central nervous system.
Company Website: https://www.arunabio.com/
Capricor Therapeutics
Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of biological therapeutics for the treatment of rare disorders. Its CAP-2003 product is comprised of exosomes isolated from the company’s proprietary cardiosphere-derived cells (CDCs). It is being developed as a next-generation therapeutic platform in regenerative medicine and as a vehicle to deliver therapies to cells in the human body.Exosome Technology: Natural Exosomes Disease Targets: Cardiovascular Disease, Duchenne Muscular Dystrophy Description of Exosome Involvement: Capricor Therapeutics is developing exosome-based therapies for a range of diseases. The company's platform utilizes exosomes derived from cardiosphere-derived cells (CDCs) to deliver therapeutic payloads, such as microRNAs, to target cells and tissues. Country: United States City/State: Beverly Hills, CA Link to Exosome Programs: https://capricor.com/pipeline/ Company Website: https://capricor.com/
Ciloa
Ciloa is a French biotech company, spin-off from the CNRS and the University of Montpellier, a pioneer in the development of vaccines and exosome-based therapies. Based in Montpellier, it was created in 2011 by Robert MAMOUN and Bernadette TRENTIN. Ciloa has an exclusive patented technology for the in vivo development of recombinant exosomes in therapeutic and preventive applications.Clara Biotech
Clara Biotech is focused on providing the tools researchers need to harness the full potential of exosomes, including therapeutic, diagnostic and clinical applications. The company is developing a high-throughput lab tool (ExoSS) that aims to automate exosome prootcols, making its world-class exosome isolation service possible in your own lab at rates up to 100 samples/hour.Codiak BioSciences
Codiak BioSciences is pioneering exosome research and development to create an entirely new class of medicines, exosome therapeutics. Its proprietary engEx™ technology platform for exosome engineering and manufacturing represents a transformative step in the treatment of disease, enabling the development of therapies for diseases that are currently considered intractable. Using this breakthrough platform, it can produce exosomes that have precise and intentionally chosen properties and make them at industrial quality and scale.Exosome Technology: Engineered Exosomes Disease Targets: Oncology, Neurology, Immunology, Rare Diseases Description of Exosome Involvement: Codiak BioSciences is developing engineered exosomes as a platform for targeted drug delivery. The company's exosomes can be designed to target specific cells and tissues, and can carry a variety of payloads, including small molecules, proteins, and nucleic acids. Country: United States City/State: Cambridge, MA Link to Exosome Programs: https://www.codiakbio.com/pipeline/ Company Website: https://www.codiakbio.com/
Cognate BioServices
Exosome Technology: Natural Exosomes Disease Targets: Oncology, Immune Disorders Description of Exosome Involvement: Cognate BioServices is a contract development and manufacturing organization (CDMO) that specializes in the production of exosomes for use in cell and gene therapy. The company's exosomes can be used to deliver therapeutic payloads, such as RNA and proteins, to target cells and tissues. Country: United States City/State: Memphis, TN Link to Exosome Programs: https://cognatebioservices.com/cell-therapy-products/exosomes/ Company Website: https://cognatebioservices.com/
Creative Medical Technology Holdings
Creative Medical Technology Holdings is a commercial stage biotechnology company committed to improving patient lives in the areas of Urology, Neurology and Orthopedics. It has a patent application that covers the use of the company’s AmnioStem product as a production tool for the generation of exosomes to regenerate damaged brain tissue after a stroke.
Cytovia Therapeutics
Exosome Technology: Natural Exosomes Disease Targets: Oncology, Infectious Diseases, Inflammatory Diseases Description of Exosome Involvement: Cytovia Therapeutics is developing exosome-based therapies for the treatment of cancer, infectious diseases, and inflammatory diseases. The company's exosomes are derived from natural killer (NK) cells and can be engineered to carry therapeutic payloads, such as cytokines and antibodies. Country: United States City/State: New York, NY Link to Exosome Programs: https://www.cytoviatx.com/therapies/ Company Website: https://www.cytoviatx.com/
Direct Biologics
Direct Biologics is a biologics manufacturer of regenerative medical products including exosomes. Its ExoFlo exosomes are isolated from donated human mesenchymal stem cells (MSCs) and purified using proprietary processing. According to the company, the benefit to its exosomes is that they are stem cell-derived and bring a wide array of growth factors to stimulate and modulate many processes within the healing cascade.
EV Therapeutics
EV Therapeutics is an exosome-based therapeutics company focusing on developing a novel immune modulator based on its proprietary tumor-derived extracellular vesicles (mTEVs) that enhance immunotherapy efficacy in advanced stage colorectal cancers (CRC) and other solid tumor cancers.
EverZom
Incorporated in September 2019, EverZom is a start-up based in France that is developing a GMP compliant extracellular vesicle manufacturing platform. As a CDMO for EVs, EVerZom aims to overcome the challenge of producing EVs at commercial scale with a breakthrough patented production method. This technology was developed in collaboration with the University of Paris and the CNRS. The process consists in applying a turbulence stimulation on cells resulting in a increase of the EV production yield by 100 times with minor impact on cell viability.
Evox Therapeutics
Evox Therapeutics is a platform technology company spearheading the development of exosome therapeutics for the treatment of life-threatening diseases. It is combining groundbreaking exosome technology from two renowned institutions in exosome research, Oxford University and the Karolinska Institutet. It has built a comprehensive IP portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas.
Exosome Technology: Engineered Exosomes Disease Targets: Rare Diseases, Metabolic Disorders, Oncology Description of Exosome Involvement: Evox Therapeutics is developing exosome-based therapeutics for a range of diseases. The company's platform allows for the engineering of exosomes to target specific cells and tissues, and to deliver a range of payloads, including RNA and proteins. Country: United Kingdom City/State: Oxford Link to Exosome Programs: https://www.evoxtx.com/pipeline/ Company Website: https://www.evoxtx.com/
ExoCoBio
Headquartered in Seoul, South Korea, ExoCoBio is focusing on stem cell-derived exosomes, to develop innovative therapeutic as well as cosmetic products. The company is exploring the use of stem cell derived-exosomes to regenerate or activate/de-activate various tissues or cells.
Exopharm Pty Ltd
Exopharm is an Australian regenerative medicine biopharmaceutical company that is seeking to develop and commercialize exosomes as therapeutic agents – initially a product called Plexaris™ and later a product called Exomeres™. Exopharm’s LEAP Technology also provides a key step in the downstream manufacturing process to isolate and purify exosomes from adult stem cells and other sources. Its LEAP Manufacturing Process has been developed to address the existing limitations in exosome purification processes. It entered into a partnership with RoosterBio in August 2017.
Exosome Diagnostics
Exosome Diagnostics is commercializing minimally invasive molecular diagnostics in blood and urine to enable doctors to select optimal therapies for cancer and other diseases. To do this, it utilizes exosomes, which are lipid bilayer covered microvesicles shed by solid tumors into body fluids, such as blood and urine. For example, its ExoDx™ Prostate Test is a simple, non-DRE, urine-based, liquid biopsy test used to diagnose and assess the risk of prostate cancer.
Exosome Plus
Exosome Plus is pioneering regenerative biotechnology with its exosome-based pharmaceutical platform (ExoThera™). It is focused on providing an “innovative proprietary regenerative pharmaceutical platform, ExoThera™, for irreversible diseases.”
Exosome Sciences
Exosome Sciences is working in collaboration with its majority shareholder, Aethlon Medical (Nasdaq:AEMD), to discover exosome-based biomarkers to diagnose and monitor Alzheimer’s disease (AD), Chronic Traumatic Encephalopathy (CTE) and other neurological disorders. It is advancing a TauSome™ biomarker (also referred to as exosomal tau) as the basis for a candidate blood test to diagnose CTE in living individuals.
Exosomics S.p.A.
Exosomics S.p.A., an Italian start-up company developing exosome-based early-stage cancer screening and molecular diagnostic tests. Exosomics has unique IP related to the isolation and selective enrichment of tumor-originated extracellular vesicles (EVs)/exosomes from complex biofluids. Its mission is to develop and commercialize a new generation of tests for cancer screening and liquid biopsy based on analysis of circulating extracellular vesicles and exosomes. The company offers a wide range of proprietary reagents and kits for cancer screening and liquid biopsy, suitable for research use and clinical diagnostics. It also has a strategic partnership with Lonza, entered into in May 2017.
Ilias Biologics Inc.
ILIAS developed a unique platform technology EXPLOR™ that makes it possible to load specific proteins into exosomes in a controllable way. Unlike the conventional methods employing passive loading of cargoes, EXPLOR™ allows active and reversible loading of target proteins into exosomes with high efficiency. ILIAS built a robust pipeline that covers inflammatory and metabolic diseases as well as cancers. Its therapeutic exosomes showed promising efficacy profiles in non-clinical studies and ILIAS is getting ready to start a clinical trial in 2021.
Invitrx Inc.
Invitrx’s EX-MSC is an exosome allograft derived from Wharton’s Jelly MSCs and is sourced from a proprietary blend of cells developed for growth and repair. Exosomes and other Extracellular Vesicles (EVs) are isolated from their parent cells and concentrated to produce the Exosomal Product.
Kimera Labs
Kimera Labs is a regenerative medicine focused biotechnology company specializing in exosome manufacturing. Its XoGlo™ product is an isolated, xeno-free, chemically defined, cell-free placental MSC derived exosome re-suspended in 0.9% normal saline. According to the company, this cosmetic product contains a multitude of growth factors, which are involved in skin repair, beautification and regeneration. The company also manufactures sterile, pharmaceutical-grade mesenchymal stem cell exosomes for future IRB-approved clinical research.Exosome Technology: Natural Exosomes Disease Targets: Regenerative Medicine, Anti-Aging Description of Exosome Involvement: Kimera Labs is a provider of exosome-based therapies for regenerative medicine and anti-aging. The company's exosomes are derived from amniotic fluid and can be used to promote tissue repair and regeneration. Country: United States City/State: Miramar, FL Link to Exosome Programs: https://kimeralabs.com/products/ Company Website: https://kimeralabs.com/
Lonza (HansaBioMed Life Sciences Ltd)
In May 2017, Lonza acquired HansaBioMed Life Sciences based in Tallinn, Estonia, a start-up company dedicated to the research and development, manufacturing, and distribution of products for the exosomes research market. Now under the Lonza brand, HansaBioMed Life Sciences Ltd (HBM-LS) develops products in the field of exosome sciences and offers an advanced portfolio of products and services for EV research. (Lonza is also the leading and strategic investor in Exosomics Group, another exosome company.)
MDimune Inc.
MDimune is a cell-derived vesicle (CDVs)-based therapeutics company that has developed a BioDrone® platform technology, which is a novel technology that uses cell-derived vesicles to achieve highly target-specific drug delivery. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. MDimune’s current programs are focused on cancer, COPD and other rare diseases.
NanoView Biosciences
NanoView Biosciences was founded on a technology platform that uniquely identifies and characterizes exosomes. Its ExoView™ platform provides the ability to measure up to 4 markers on a single extracellular vesicle, with single binding event sensitivities.
Oasis Diagnostics® Corporation
As a pioneer in the area of salivary diagnostics, Oasis Diagnostics® Corporation provides tools for the simple and immediate isolation of exosomes, cell free DNA, cell free RNA [miRNA, mRNA] from saliva specimens. As part of its long term goals in this area the Company is involved in the characterization of salivary exosomes, particularly looking at the nature of salivary exosomes, what they are, what role they play, how they can be employed as diagnostics to pinpoint specific diseases and whether there are unique differences between exosomes from normal, healthy individuals and those with targeted diseases.
OmniSpirant
OmniSpirant has a patent pending platform technology based on inhaled bioengineered stem cell exosomes, which are capable of efficient intracellular delivery of a variety of therapeutic cargoes to effectively treat respiratory diseases. Its engineered stem cell exosomes will initially be used to develop a first-in-class regenerative gene therapy for Cystic Fibrosis. The prorietatry mucus penetrating exosomes have similar transformative potential for treating many other respiratory diseases.
Organicell
Organicell™ describes itself as a fully integrated Exosome Therapeutics Company. Its Zofin™ product contains approximately 400 billion exosomes per milliliter quantified in every batch by Nanosight technology. Exosomes are nanovesicles that contain protein and microRNA that can be transferred to other cells to support tissue repair and homeostasis.
PureTech Health
Exosome Technology: Engineered Exosomes Disease Targets: Immune Disorders, Cancer, Neurological Disorders Description of Exosome Involvement: PureTech Health is developing exosome-based therapies for a range of diseases. The company's platform utilizes engineered exosomes to deliver therapeutic payloads, such as RNA and proteins, to target cells and tissues. Country: United States City/State: Boston, MA Link to Exosome Programs: https://www.puretechhealth.com/pipeline/exosome-programs Company Website: https://www.puretechhealth.com/
Regen Suppliers
Based in Scottsdale, Arizona, Regen Suppliers announced its exosome industry involvement with a January 16, 2020, announcement stating that the company offers ReBella and ReBellaXO, umbilical stem cell and exosome products used for regenerative aesthetic procedures involving hair, facial and sexual rejuvenation. According to the company, ReBellaXO is an MSC Derived Exosome Biologic that is a “minimally manipulated allograft derived from full term, post c-section umbilical cord tissue and Wharton’s Jelly.”
ReNeuron
ReNeuron is a UK-based stem cell company developing therapies for unmet medical needs. ReNeuron has developed a technological process enabling it to produce exosomes from a cell line, such as its proprietary CTX neural stem cell line under different culture conditions, which can in turn be harvested at a commercially relevant scale.Exosome Technology: Engineered Exosomes Disease Targets: Stroke, Retinal Diseases Description of Exosome Involvement: ReNeuron Group is developing exosome-based therapies for the treatment of stroke and retinal diseases. The company's exosomes are engineered to deliver therapeutic payloads, such as microRNAs and proteins, to target cells and tissues. Country: United Kingdom City/State: South Wales Link to Exosome Programs: https://www.reneuron.com/pipeline/ Company Website: https://www.reneuron.com/
RoosterBio Inc.
In August 2017, RoosterBio Inc and Exopharm Pty Ltd announce an agreement under which they will work together on a Stem Cell Exomere Program, aimed at bringing high-grade therapeutic extracellular vesicles/exosomes derived from adult stem cells into clinical practice. According to the companies, they are working together to develop and implement a standardized, scalable, commercially-viable biomanufacturing process utilizing Exopharm’s Exomere technology in order to enable rapid clinical translation with a cGMP-compliant Exomere product into regenerative medicine (RM) applications.
Stem Cells Group
Exosome Technology: Natural Exosomes Disease Targets: Regenerative Medicine Description of Exosome Involvement: Stem Cells Group is a global provider of regenerative medicine products and services, including exosome-based therapies. The company's exosomes are derived from mesenchymal stem cells (MSCs) and can be used to promote tissue repair and regeneration. Country: United States City/State: Miami, FL Link to Exosome Programs: https://www.stemcellsgroup.com/exosome-therapy/ Company Website: https://www.stemcellsgroup.com/
Stemcell Medicine Ltd.
Announced January 2018, Stem Cell Medicine Ltd. (SCM) has licensed an innovative exosome-based technology for the treatment of neurodegenerative and neuropsychiatric indications, specifically, autism spectrum disorder (ASD). The treatment is based on vesicles, exosomes, derived from adult stem cells (MSC-exo) that are administered intranasally. The technology was developed by Professor Dani Offen, Sackler School of Medicine, Sagol School of Neurosciences Tel Aviv University and was licensed from Ramot, the Business Engagement Center at Tel Aviv University.
TAVEC Pharmaceuticals
Tavec is developing the next-generation of potent anti-cancer gene therapies using the power of injectable, miRNA loaded exosomes. It has demonstrated an ability to deliver high levels of specific miRNA, including widely known cancer disruptive targets such as miR195, directly to cancer cells. Using in vivo models, its miRNA-loaded exosomes inhibit cancer growth and prolong lifespan. The company is focused on exploiting a cancer cells natural pre-disposition to taking up large quantities of certain types of exosomes to insert microRNAs that will disrupt the cancer growth instruction set.
The Cell-Factory BVBA (Esperite)
The Cell Factory, is a platform-based biotech company focused on innovative products development, clinical translation and commercialization. It is developing extracellular vesicles (EVs) and exosomes, in particular allogenic “off-the-shelf” MSC-derived EVs and exosomes to used as inhibitors of acute and chronic inflammation and immunosuppressants in the treatment of unmet medical needs. Its target diseases are Crohn’s disease, drug-resistant epilepsy, and others. It fully owns a patent family on broad applications of MSC-derived EVs and exosomes in treatment of various inflammatory diseases.
Unicyte AG
Headquartered in Oberdorf, Switzerland, Unicyte AG evolved from a fifteen year research collaboration with Prof Giovanni Camussi, a leading expert on extracellular vesicles and stem cells from the University of Turin and Fresenius Medical Care KGaA, the world’s largest provider of products and services for individuals with renal diseases. As a pioneer in liver stem cells and nano-extracellular vesicles, the company is dedicated to improving the lives of patients with kidney or liver disease, diabetes, and cancer. Unicyte was founded in 2015 as an independent affiliate of Fresenius Medical Care and is headquartered in Oberdorf NW, Switzerland.VivaZome Therapeutics Pty Ltd
VivaZome Therapeutics Pty Ltd is a privately-held Australian biotech company, based in Melbourne, Victoria. It was formed to develop and commercialise exosome-based therapies, with a focus on treatments for debilitating and/or life-threatening disorders which are not adequately managed by current therapies.XOStem Inc.
XOStem, Inc. was registered as a company in Delaware on May 9, 2018. While there is limited information available about the company, XOStem appears to be developing engineered exosomes for regenerative skin care, joint care, and other therapies.
Adapted and updated from: https://bioinformant.com/exosomes/
Related: TOP COMPANIES IN CAR NK-CELL THERAPY
Comments
Post a Comment